Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA.
Robertson MJ, et al. Among authors: thornton d.
J Clin Oncol. 2007 May 1;25(13):1741-6. doi: 10.1200/JCO.2006.09.3146. Epub 2007 Mar 26.
J Clin Oncol. 2007.
PMID: 17389337
Clinical Trial.